Literature DB >> 25255107

The current role of imaging in head and neck cancer: a clinician's perspective.

Michael F Schlumpf1, Stephan Haerle1.   

Abstract

Imaging head and neck cancer is crucial for treatment decisions and follow-up of patients. The choice of the appropriate imaging modality for staging and re-staging head and neck cancer can be troublesome. This review highlights the important questions of imaging from a clinician's perspective. The recommendations focus on mucosal squamous cell carcinoma of the head and neck since this is the most common one.

Entities:  

Mesh:

Year:  2014        PMID: 25255107     DOI: 10.4414/smw.2014.14015

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  4 in total

1.  (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.

Authors:  Thomas Bird; Sally Barrington; Selvam Thavaraj; Jean-Pierre Jeannon; Andrew Lyons; Richard Oakley; Ricard Simo; Mary Lei; Teresa Guerrero Urbano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-28       Impact factor: 9.236

2.  Evaluation of a post-treatment follow-up program in patients with oral squamous cell carcinoma.

Authors:  Andre Peisker; Gregor Franziskus Raschke; Arndt Guentsch; Paul Luepke; Korosh Roshanghias; Stefan Schultze-Mosgau
Journal:  Clin Oral Investig       Date:  2016-02-29       Impact factor: 3.573

3.  A critical appraisal of the quality of head and neck cancer imaging guidelines using the AGREE II tool: A EuroAIM initiative.

Authors:  Valeria Romeo; Arnaldo Stanzione; Sirio Cocozza; Lorenzo Ugga; Renato Cuocolo; Arturo Brunetti; Sotirios Bisdas
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

4.  Value of FDG-PET/MR in Oral Focus Assessment in Head and Neck Cancer Patients-A Feasibility Study.

Authors:  Silvio Valdec; Fabienne A Bosshard; Martin Hüllner; Dominic R Schwaninger; Larissa Stocker; Barbara Giacomelli-Hiestand; Bernd Stadlinger
Journal:  Front Med (Lausanne)       Date:  2022-03-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.